Novel Cholera Conjugate Vaccine

Cholera remains a major health issue, especially for young children, with millions of cases and thousands of deaths annually. Current oral cholera vaccines (OCVs) have low efficacy in young children and short protection duration, requiring frequent mass vaccination campaigns instead of routine immunization. The International Vaccine Institute (IVI), with RIGHT Foundation’s grant, is developing an injectable Cholera Conjugate Vaccine (CCV) to address these limitations. By leveraging polysaccharide conjugation, CCV could provide higher efficacy, longer-lasting protection, and integration into routine immunization (EPI). IVI’s research and clinical trials, backed by RIGHT Foundation, will ensure CCV meets WHO pre-qualification standards for broader accessibility. This breakthrough could significantly reduce cholera cases, deaths, and reliance on mass campaigns, contributing to long-term global cholera control.